Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Prescribing Guidelines From US FDA Could Be A While After NASEM Report

Executive Summary

National Academies report identifies gaps in the existing data – including on the question of whether developing prescribing guidelines would even have an impact on the opioid epidemic.

You may also be interested in...



Califf Says Opioid Labeling Changes, Withdrawals Still Possible

The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.

Non-Opioid Pain Treatments Likely Not Eligible For Accelerated Approval, US FDA Says

Other expedited pathways like fast track, priority review or breakthrough could be appropriate, according to new draft guidance.

US FDA Needs ‘More Streamlined’ REMS Enforcement Authority, Inspector General Says

Additional power would allow the agency to punish 'simple' REMS violations and improve administration of risk management programs, according to a new report looking at FDA's oversight of opioids.

Related Content

Topics

UsernamePublicRestriction

Register

PS141409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel